Hepatitis C drug Sofosbuvir approved for use on NHS

Hepatitis C People with the most common form of the virus will be prescribed the new drug on the NHS

Experts have approved the use of a new drug to treat hepatitis C on the NHS.

Sofosbuvir cures the majority of patients, but costs £36,000 per course. It is to be made available to people with the most common form of the virus.

It is estimated 50,000 people in Scotland have hepatitis C.

The Scottish Medicines Consortium (SMC) decided the high cost of offering the drug to such a large group of patients was outweighed by its effectiveness.

People with less common forms of the virus will be offered the new drug if conventional treatment fails.

Hepatitis C is contracted through contaminated needles, blood or sexual intercourse, and causes liver failure or liver cancer.

Current treatment involves regular injections for up to a year with a drug which has unpleasant side effects and works for only 60-70% of patients.

Sofosbuvir is one of a new generation of treatments which are much more effective but come with a high price tag.

A course of the drug takes just 12 weeks.

A statement by the SMC said: "The consortium accepted sofosbuvir for restricted use because it is effective and addresses an unmet treatment need."

More on This Story

The BBC is not responsible for the content of external Internet sites

More Scotland stories

RSS

Features

  • Vegan tagsWhole hog

    Glasgow going all out to embrace veganism as anniversary marked


  • Man's hands putting ring on woman's fingerName changer

    Why do wives take a man's name after marriage?


  • Mobil canopies on the A6 at Red Hill, LeicestershireEnglish heritage

    Zebra crossings to bus stations: unusual listed buildings


  • Man with typewriterLove to Patrick

    The official whose over-familiar letters infuriated his boss


  • GoFig india violenceGo Figure

    The week in numbers with our Go Figure images


BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.